1 Market Overview

• 1.1 Product Overview and Scope
• 1.2 Market Estimation Caveats and Base Year
• 1.3 Classification of ADHD Medication by Type
  • 1.3.1 Overview: Global ADHD Medication Market Size by Type: 2019 Versus 2023 Versus 2030
  • 1.3.2 Global ADHD Medication Consumption Value Market Share by Type in 2023
  • 1.3.3 Stimulant
  • 1.3.4 Non-stimulant
• 1.4 Global ADHD Medication Market by Application
  • 1.4.1 Overview: Global ADHD Medication Market Size by Application: 2019 Versus 2023 Versus 2030
  • 1.4.2 Attention Deficit
  • 1.4.3 Hyperactivity/impulse Control Disorder
  • 1.4.4 Hybrid
• 1.5 Global ADHD Medication Market Size & Forecast
• 1.6 Global ADHD Medication Market Size and Forecast by Region
  • 1.6.1 Global ADHD Medication Market Size by Region: 2019 VS 2023 VS 2030
  • 1.6.2 Global ADHD Medication Market Size by Region, (2019-2030)
  • 1.6.3 North America ADHD Medication Market Size and Prospect (2019-2030)
  • 1.6.4 Europe ADHD Medication Market Size and Prospect (2019-2030)
  • 1.6.5 Asia-Pacific ADHD Medication Market Size and Prospect (2019-2030)
  • 1.6.6 South America ADHD Medication Market Size and Prospect (2019-2030)
  • 1.6.7 Middle East & Africa ADHD Medication Market Size and Prospect (2019-2030)

2 Company Profiles

• 2.1 Takeda
  • 2.1.1 Takeda Details
  • 2.1.2 Takeda Major Business
  • 2.1.3 Takeda ADHD Medication Product and Solutions
  • 2.1.4 Takeda ADHD Medication Revenue, Gross Margin and Market Share (2019-2024)
  • 2.1.5 Takeda Recent Developments and Future Plans
• 2.2 Johnson & Johnson
  • 2.2.1 Johnson & Johnson Details
  • 2.2.2 Johnson & Johnson Major Business
  • 2.2.3 Johnson & Johnson ADHD Medication Product and Solutions
  • 2.2.4 Johnson & Johnson ADHD Medication Revenue, Gross Margin and Market Share (2019-2024)
  • 2.2.5 Johnson & Johnson Recent Developments and Future Plans
• 2.3 Novartis
  • 2.3.1 Novartis Details
  • 2.3.2 Novartis Major Business
  • 2.3.3 Novartis ADHD Medication Product and Solutions
  • 2.3.4 Novartis ADHD Medication Revenue, Gross Margin and Market Share (2019-2024)
  • 2.3.5 Novartis Recent Developments and Future Plans
• 2.4 Eli Lilly
  • 2.4.1 Eli Lilly Details
  • 2.4.2 Eli Lilly Major Business
  • 2.4.3 Eli Lilly ADHD Medication Product and Solutions
  • 2.4.4 Eli Lilly ADHD Medication Revenue, Gross Margin and Market Share (2019-2024)
  • 2.4.5 Eli Lilly Recent Developments and Future Plans
• 2.5 Tris Pharma, Inc
  • 2.5.1 Tris Pharma, Inc Details
  • 2.5.2 Tris Pharma, Inc Major Business
  • 2.5.3 Tris Pharma, Inc ADHD Medication Product and Solutions
  • 2.5.4 Tris Pharma, Inc ADHD Medication Revenue, Gross Margin and Market Share (2019-2024)
  • 2.5.5 Tris Pharma, Inc Recent Developments and Future Plans
• 2.6 Neos Therapeutics
  • 2.6.1 Neos Therapeutics Details
  • 2.6.2 Neos Therapeutics Major Business
  • 2.6.3 Neos Therapeutics ADHD Medication Product and Solutions
  • 2.6.4 Neos Therapeutics ADHD Medication Revenue, Gross Margin and Market Share (2019-2024)
  • 2.6.5 Neos Therapeutics Recent Developments and Future Plans
• 2.7 Mallinckrodt
  • 2.7.1 Mallinckrodt Details
  • 2.7.2 Mallinckrodt Major Business
  • 2.7.3 Mallinckrodt ADHD Medication Product and Solutions
  • 2.7.4 Mallinckrodt ADHD Medication Revenue, Gross Margin and Market Share (2019-2024)
  • 2.7.5 Mallinckrodt Recent Developments and Future Plans
• 2.8 Amneal Pharmaceuticals
  • 2.8.1 Amneal Pharmaceuticals Details
  • 2.8.2 Amneal Pharmaceuticals Major Business
  • 2.8.3 Amneal Pharmaceuticals ADHD Medication Product and Solutions
  • 2.8.4 Amneal Pharmaceuticals ADHD Medication Revenue, Gross Margin and Market Share (2019-2024)
  • 2.8.5 Amneal Pharmaceuticals Recent Developments and Future Plans
• 2.9 Noven Pharmaceuticals
  • 2.9.1 Noven Pharmaceuticals Details
  • 2.9.2 Noven Pharmaceuticals Major Business
  • 2.9.3 Noven Pharmaceuticals ADHD Medication Product and Solutions
  • 2.9.4 Noven Pharmaceuticals ADHD Medication Revenue, Gross Margin and Market Share (2019-2024)
  • 2.9.5 Noven Pharmaceuticals Recent Developments and Future Plans
• 2.10 Purdue Parma
  • 2.10.1 Purdue Parma Details
  • 2.10.2 Purdue Parma Major Business
  • 2.10.3 Purdue Parma ADHD Medication Product and Solutions
  • 2.10.4 Purdue Parma ADHD Medication Revenue, Gross Margin and Market Share (2019-2024)
  • 2.10.5 Purdue Parma Recent Developments and Future Plans
• 2.11 Zhengda Fenghai
  • 2.11.1 Zhengda Fenghai Details
  • 2.11.2 Zhengda Fenghai Major Business
  • 2.11.3 Zhengda Fenghai ADHD Medication Product and Solutions
  • 2.11.4 Zhengda Fenghai ADHD Medication Revenue, Gross Margin and Market Share (2019-2024)
  • 2.11.5 Zhengda Fenghai Recent Developments and Future Plans

3 Market Competition, by Players

• 3.1 Global ADHD Medication Revenue and Share by Players (2019-2024)
• 3.2 Market Share Analysis (2023)
  • 3.2.1 Market Share of ADHD Medication by Company Revenue
  • 3.2.2 Top 3 ADHD Medication Players Market Share in 2023
  • 3.2.3 Top 6 ADHD Medication Players Market Share in 2023
• 3.3 ADHD Medication Market: Overall Company Footprint Analysis
  • 3.3.1 ADHD Medication Market: Region Footprint
  • 3.3.2 ADHD Medication Market: Company Product Type Footprint
  • 3.3.3 ADHD Medication Market: Company Product Application Footprint
• 3.4 New Market Entrants and Barriers to Market Entry
• 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

• 4.1 Global ADHD Medication Consumption Value and Market Share by Type (2019-2024)
• 4.2 Global ADHD Medication Market Forecast by Type (2025-2030)

5 Market Size Segment by Application

• 5.1 Global ADHD Medication Consumption Value Market Share by Application (2019-2024)
• 5.2 Global ADHD Medication Market Forecast by Application (2025-2030)

6 North America

• 6.1 North America ADHD Medication Consumption Value by Type (2019-2030)
• 6.2 North America ADHD Medication Market Size by Application (2019-2030)
• 6.3 North America ADHD Medication Market Size by Country
  • 6.3.1 North America ADHD Medication Consumption Value by Country (2019-2030)
  • 6.3.2 United States ADHD Medication Market Size and Forecast (2019-2030)
  • 6.3.3 Canada ADHD Medication Market Size and Forecast (2019-2030)
  • 6.3.4 Mexico ADHD Medication Market Size and Forecast (2019-2030)

7 Europe

• 7.1 Europe ADHD Medication Consumption Value by Type (2019-2030)
• 7.2 Europe ADHD Medication Consumption Value by Application (2019-2030)
• 7.3 Europe ADHD Medication Market Size by Country
  • 7.3.1 Europe ADHD Medication Consumption Value by Country (2019-2030)
  • 7.3.2 Germany ADHD Medication Market Size and Forecast (2019-2030)
  • 7.3.3 France ADHD Medication Market Size and Forecast (2019-2030)
  • 7.3.4 United Kingdom ADHD Medication Market Size and Forecast (2019-2030)
  • 7.3.5 Russia ADHD Medication Market Size and Forecast (2019-2030)
  • 7.3.6 Italy ADHD Medication Market Size and Forecast (2019-2030)

8 Asia-Pacific

• 8.1 Asia-Pacific ADHD Medication Consumption Value by Type (2019-2030)
• 8.2 Asia-Pacific ADHD Medication Consumption Value by Application (2019-2030)
• 8.3 Asia-Pacific ADHD Medication Market Size by Region
  • 8.3.1 Asia-Pacific ADHD Medication Consumption Value by Region (2019-2030)
  • 8.3.2 China ADHD Medication Market Size and Forecast (2019-2030)
  • 8.3.3 Japan ADHD Medication Market Size and Forecast (2019-2030)
  • 8.3.4 South Korea ADHD Medication Market Size and Forecast (2019-2030)
  • 8.3.5 India ADHD Medication Market Size and Forecast (2019-2030)
  • 8.3.6 Southeast Asia ADHD Medication Market Size and Forecast (2019-2030)
  • 8.3.7 Australia ADHD Medication Market Size and Forecast (2019-2030)

9 South America

• 9.1 South America ADHD Medication Consumption Value by Type (2019-2030)
• 9.2 South America ADHD Medication Consumption Value by Application (2019-2030)
• 9.3 South America ADHD Medication Market Size by Country
  • 9.3.1 South America ADHD Medication Consumption Value by Country (2019-2030)
  • 9.3.2 Brazil ADHD Medication Market Size and Forecast (2019-2030)
  • 9.3.3 Argentina ADHD Medication Market Size and Forecast (2019-2030)

10 Middle East & Africa

• 10.1 Middle East & Africa ADHD Medication Consumption Value by Type (2019-2030)
• 10.2 Middle East & Africa ADHD Medication Consumption Value by Application (2019-2030)
• 10.3 Middle East & Africa ADHD Medication Market Size by Country
  • 10.3.1 Middle East & Africa ADHD Medication Consumption Value by Country (2019-2030)
  • 10.3.2 Turkey ADHD Medication Market Size and Forecast (2019-2030)
  • 10.3.3 Saudi Arabia ADHD Medication Market Size and Forecast (2019-2030)
  • 10.3.4 UAE ADHD Medication Market Size and Forecast (2019-2030)

11 Market Dynamics

• 11.1 ADHD Medication Market Drivers
• 11.2 ADHD Medication Market Restraints
• 11.3 ADHD Medication Trends Analysis
• 11.4 Porters Five Forces Analysis
  • 11.4.1 Threat of New Entrants
  • 11.4.2 Bargaining Power of Suppliers
  • 11.4.3 Bargaining Power of Buyers
  • 11.4.4 Threat of Substitutes
  • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

• 12.1 ADHD Medication Industry Chain
• 12.2 ADHD Medication Upstream Analysis
• 12.3 ADHD Medication Midstream Analysis
• 12.4 ADHD Medication Downstream Analysis

13 Research Findings and Conclusion

14 Appendix

• 14.1 Methodology
• 14.2 Research Process and Data Source

Stimulants are the best and most common type of medication used to treat ADHD.
According to our (Global Info Research) latest study, the global ADHD Medication market size was valued at US$ million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of %during review period.
Johnson & Johnson is the largest manufacturer of ADHD medication in China, has a market share of over 40%. Other key players include Eli Lilly and Zhengda Fenghai, etc. Geographically speaking, East China is the largest market, has a market share of about 25%. In terms of type, both stimulants and non-stimulants account for about 50% of market share. In terms of application, hybrid is the dominant field using ADHD medication, has a market share of over 80%.
This report is a detailed and comprehensive analysis for global ADHD Medication market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global ADHD Medication market size and forecasts, in consumption value ($ Million), 2019-2030
Global ADHD Medication market size and forecasts by region and country, in consumption value ($ Million), 2019-2030
Global ADHD Medication market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030
Global ADHD Medication market shares of main players, in revenue ($ Million), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for ADHD Medication
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global ADHD Medication market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Takeda, Johnson & Johnson, Novartis, Eli Lilly, Tris Pharma, Inc, Neos Therapeutics, Mallinckrodt, Amneal Pharmaceuticals, Noven Pharmaceuticals, Purdue Parma, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
ADHD Medication market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segmentation
ADHD Medication market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Stimulant
Non-stimulant
Market segment by Application
Attention Deficit
Hyperactivity/impulse Control Disorder
Hybrid
Market segment by players, this report covers
Takeda
Johnson & Johnson
Novartis
Eli Lilly
Tris Pharma, Inc
Neos Therapeutics
Mallinckrodt
Amneal Pharmaceuticals
Noven Pharmaceuticals
Purdue Parma
Zhengda Fenghai
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe ADHD Medication product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of ADHD Medication, with revenue, gross margin, and global market share of ADHD Medication from 2019 to 2024.
Chapter 3, the ADHD Medication competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and ADHD Medication market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of ADHD Medication.
Chapter 13, to describe ADHD Medication research findings and conclusion.